Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis

Chest

Volumn 146, Issue 4, 2014, Pages 1055-1063

  Jaffar, Jade ^a,b   Unger, Sofia ^a   Corte, Tamera J ^b   Keller, Michael ^b   Wolters, Paul J ^c   Richeldi, Luca ^d,e   Cerri, Stefania ^d   Prêle, Cecilia M ^f,g   Hansbro, Philip M ^h   Argraves, William Scott ⁱ   Oliver, Rema A ^j,k   Oliver, Brian G ^a   Black, Judith L ^a,b   Burgess, Janette K ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h Centre for Asthma and Respiratory Diseases   (Australia)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBULIN; FIBULIN 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN;

AGED; ARTICLE; CLINICAL ARTICLE; COMPOSITE PHYSIOLOGIC INDEX; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG DIFFUSION CAPACITY; LUNG FIBROBLAST; LUNG PARENCHYMA; MALE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT PARAMETERS; SURVIVAL TIME; TOTAL LUNG CAPACITY; AUSTRALIA; CLINICAL TRIAL; CULTURE TECHNIQUE; FIBROBLAST; FOLLOW UP; IMMUNOHISTOCHEMISTRY; ITALY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; UNITED STATES; VERY ELDERLY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AUSTRALIA; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL CULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; ITALY; MALE; MIDDLE AGED; UNITED STATES;

EID: 84907919354     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2688     Document Type: Article

References (28)

1. Demedts M, Wells AU, Antó JM, et al. Interstitial lung diseases: An epidemiological overview. Eur Respir J Suppl. 2001; 32 : 2s - 16s.
2. Raghu G, Behr J, Brown KK, et al; ARTEMIS-IPF Investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med. 2013; 158 ( 9 ): 641 - 649.
3. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: A randomised controlled trial. Thorax. 2013; 68 ( 2 ): 155 - 162.
4. Araya J, Nishimura SL. Fibrogenic reactions in lung disease. Annu Rev Pathol. 2010; 5 : 77 - 98.
5. Tschumperlin DJ, Jones JC, Senior RM. The fibrotic matrix in control: does the extracellular matrix drive progression of idiopathic pulmonary fibrosis? A m J Respir Crit Care Med. 2012; 186 ( 9 ): 814 - 816.
6. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012; 159 ( 4 ): 218 - 227.
7. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185 ( 1 ): 67 - 76.
8. Miosge N, Götz W, Sasaki T, Chu ML, Timpl R, Herken R. The extracellular matrix proteins fibulin-1 and fibulin-2 in the early human embryo. Histochem J. 1996; 28 ( 2 ): 109 - 116.
9. Kostka G, Giltay R, Bloch W, et al. Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. Mol Cell Biol. 2001; 21 ( 20 ): 7025 - 7034.
10. Beers MF, Morrisey EE. The three R's of lung health and disease: repair, remodeling, and regeneration. J Clin Invest. 2011; 121 ( 6 ): 2065 - 2073.
11. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res. 2012; 347 ( 1 ): 103 - 116.
12. Roark EF, Keene DR, Haudenschild CC, Godyna S, Little CD, Argraves WS. The association of human fibulin-1 with elastic fibers: An immunohistological, ultrastructural, and RNA study. J Histochem Cytochem. 1995; 43 ( 4 ): 401 - 411.
13. Lau JY, Oliver BG, Baraket M, et al. Fibulin-1 is increased in asthma-a novel mediator of airway remodeling? PLoS ONE. 2010; 5 ( 10 ): e13360.
14. Royce SG, Cheng V, Samuel CS, Tang ML. The regulation of fibrosis in airway remodeling in asthma. Mol Cell Endocrinol. 2012; 351 ( 2 ): 167 - 175.
15. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008; 233 ( 2 ): 109 - 122.
16. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 ( 6 ): 788 - 824.
17. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013; 42 ( 3 ): 750 - 757.
18. Bland JM, Altman DG. Measurement error. BMJ. 1996; 313 ( 7059 ): 744.
19. Neiman M, Hedberg JJ, Dönnes PR, et al. Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment. J Proteome Res. 2011; 10 ( 11 ): 4925 - 4934.
20. Liu C, Zhang N, Yu H, et al. Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Placenta. 2011; 32 ( 2 ): 168 - 174.
21. Calabresi C, Arosio B, Galimberti L, et al. Natural aging, expression of fibrosis-related genes and collagen deposition in rat lung. Exp Gerontol. 2007; 42 ( 10 ): 1003 - 1011.
22. Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycan deposition in pulmonary fibrosis. A m J Respir Crit Care Med. 1996; 154 ( 6 pt 1 ): 1819 - 1828.
23. LeSaux O, Teeters K, Miyasato S, et al. The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties. Am J Physiol Lung Cell Mol Physiol. 2008; 295 ( 6 ): L1007 - L1017.
24. Argraves WS, Tanaka A, Smith EP, et al. Fibulin-1 and fibrinogen in human atherosclerotic lesions. Histochem Cell Biol. 2009; 132 ( 5 ): 559 - 565.
25. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. N at Rev Drug Discov. 2010; 9 ( 2 ): 129 - 140.
26. Liu F, Mih JD, Shea BS, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol. 2010; 190 ( 4 ): 693 - 706.
27. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364 ( 16 ): 1503 - 1512.
28. Naik PK, Bozyk PD, Bentley JK, et al; COMET Investigators. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. A m J Physiol Lung Cell Mol Physiol. 2012; 303 ( 12 ): L1046 - L1056.